Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
0 |
-2.94 |
N/A |
N/A |
2024-04-02 |
2023-12 |
0 |
-39.4 |
N/A |
N/A |
2023-11-13 |
2023-09 |
0 |
-15.27 |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
-25.2 |
N/A |
N/A |
2023-05-15 |
2023-03 |
0 |
-21 |
N/A |
N/A |
2023-04-03 |
2022-12 |
0 |
-23.1 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2018-08-12 |
ANTIBODY INVESTMENTS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2022-11-22 |
FRIEBERG JACOB B |
Director |
0.00 |
Stock Award(Grant) |
2024-02-07 |
FRIEDBERG ALBERT D |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Stock Award(Grant) |
2020-07-26 |
LEONARD JOHN E |
Officer |
2.01K |
Conversion of Exercise of derivative security |
2020-09-02 |
ROYER SCOTT E |
Chief Financial Officer |
4.50K |
Conversion of Exercise of derivative security |
2023-12-25 |
VAN STRYDONCK GERALD E |
Director |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
AIGH Capital Management LLC |
90.17K |
481.52K |
0.14% |
2023-06-29 |
Vanguard Group Inc |
48.86K |
260.90K |
0.07% |
2022-12-30 |
Telemetry Investments, L.L.C. |
27.73K |
268.11K |
0.04% |
2023-06-29 |
Geode Capital Management, LLC |
16.68K |
89.07K |
0.03% |
2023-06-29 |
Citadel Advisors Llc |
6.87K |
36.70K |
0.01% |
2023-06-29 |
State Street Corporation |
4.76K |
25.42K |
0.01% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
35.63K |
190.28K |
0.05% |
2023-05-30 |
Fidelity Extended Market Index Fund |
10.94K |
66.50K |
0.02% |
2023-06-29 |
Vanguard Extended Market Index Fund |
12.59K |
67.22K |
0.02% |
Split |
Date |
1 : 14 |
2024-02-20 |
1 : 15 |
2023-09-26 |